Apriem Advisors Has Increased Annaly Capital Mgmt (NLY) Stake By $734,400; Cadian Capital Management LP Has Increased Portola Pharmaceuticals (PTLA) Position By $45.40 Million

February 20, 2018 - By Vivian Park

Cadian Capital Management Lp increased Portola Pharmaceuticals Inc (PTLA) stake by 257.85% reported in 2017Q3 SEC filing. Cadian Capital Management Lp acquired 840,700 shares as Portola Pharmaceuticals Inc (PTLA)’s stock rose 22.73%. The Cadian Capital Management Lp holds 1.17M shares with $63.04M value, up from 326,043 last quarter. Portola Pharmaceuticals Inc now has $3.17 billion valuation. The stock increased 1.99% or $0.95 during the last trading session, reaching $48.64. About 372,985 shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 51.17% since February 20, 2017 and is uptrending. It has outperformed by 34.47% the S&P500.

Apriem Advisors increased Annaly Capital Mgmt (NLY) stake by 41.1% reported in 2017Q3 SEC filing. Apriem Advisors acquired 61,200 shares as Annaly Capital Mgmt (NLY)’s stock rose 6.28%. The Apriem Advisors holds 210,120 shares with $2.56M value, up from 148,920 last quarter. Annaly Capital Mgmt now has $12.06 billion valuation. The stock decreased 2.62% or $0.28 during the last trading session, reaching $10.4. About 5.93 million shares traded. Annaly Capital Management, Inc. (NYSE:NLY) has risen 6.73% since February 20, 2017 and is uptrending. It has underperformed by 9.97% the S&P500.

Apriem Advisors decreased Ishares 1 (CSJ) stake by 2,951 shares to 2,200 valued at $232,000 in 2017Q3. It also reduced S B A Communications stake by 4,000 shares and now owns 5,000 shares. Schwab Us Small Cap Etf (SCHA) was reduced too.

Investors sentiment increased to 1.46 in 2017 Q3. Its up 0.39, from 1.07 in 2017Q2. It improved, as 42 investors sold NLY shares while 113 reduced holdings. 61 funds opened positions while 165 raised stakes. 592.53 million shares or 12.10% more from 528.56 million shares in 2017Q2 were reported. 260,070 are held by Janney Montgomery Scott Lc. American Financial Group Inc Inc reported 0.19% of its portfolio in Annaly Capital Management, Inc. (NYSE:NLY). Paragon Mngmt owns 24,583 shares or 0.12% of their US portfolio. Price T Rowe Assoc Md reported 0% in Annaly Capital Management, Inc. (NYSE:NLY). Investment Centers Of America Inc reported 127,564 shares stake. Nfc Invs Ltd Liability Com holds 0.16% or 39,200 shares in its portfolio. Fuller & Thaler Asset reported 8,200 shares or 0% of all its holdings. Banque Pictet Cie owns 36,000 shares or 0.01% of their US portfolio. Zweig owns 13,600 shares or 0.01% of their US portfolio. Pzena Management Limited Liability Com accumulated 11,795 shares. Citadel Advsrs holds 978,504 shares or 0.01% of its portfolio. Dnb Asset Management As reported 0.08% in Annaly Capital Management, Inc. (NYSE:NLY). Geode Mgmt Limited Liability Company has 11.49 million shares for 0.05% of their portfolio. Beck Management Ltd Liability Company invested 1.87% of its portfolio in Annaly Capital Management, Inc. (NYSE:NLY). Martingale Asset Management Lp invested in 3.18 million shares or 0.52% of the stock.

Among 10 analysts covering Annaly Capital Management Inc (NYSE:NLY), 1 have Buy rating, 1 Sell and 8 Hold. Therefore 10% are positive. Annaly Capital Management Inc had 26 analyst reports since August 6, 2015 according to SRatingsIntel. FBR Capital upgraded Annaly Capital Management, Inc. (NYSE:NLY) on Friday, October 9 to “Mkt Perform” rating. On Tuesday, February 23 the stock rating was upgraded by FBR Capital to “Outperform”. The firm has “Buy” rating by Nomura given on Wednesday, August 12. Wood maintained the stock with “Market Perform” rating in Friday, August 14 report. Compass Point upgraded it to “Buy” rating and $11 target in Thursday, August 13 report. On Thursday, February 15 the stock rating was maintained by Keefe Bruyette & Woods with “Hold”. The company was upgraded on Tuesday, February 13 by Compass Point. The stock has “Underperform” rating by Bank of America on Thursday, December 15. The firm earned “Market Perform” rating on Monday, January 18 by Wells Fargo. On Sunday, August 16 the stock rating was maintained by Wood with “Hold”.

Since December 15, 2017, it had 0 insider purchases, and 1 insider sale for $563,950 activity. $563,950 worth of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) was sold by Wolff Henry Ward.

Cadian Capital Management Lp decreased Blueprint Medicines Corp stake by 143,137 shares to 313,965 valued at $21.87M in 2017Q3. It also reduced Collegium Pharmaceutical Inc stake by 197,817 shares and now owns 2.06M shares. Tableau Software Inc (NYSE:DATA) was reduced too.

Investors sentiment increased to 2.16 in 2017 Q3. Its up 0.85, from 1.31 in 2017Q2. It improved, as 20 investors sold PTLA shares while 37 reduced holdings. 38 funds opened positions while 85 raised stakes. 56.33 million shares or 15.80% more from 48.64 million shares in 2017Q2 were reported. Kazazian Asset Management Ltd Llc owns 0.81% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 12,241 shares. Hightower Advsrs Lc owns 4,045 shares or 0% of their US portfolio. Principal Financial Grp invested 0% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). First Mercantile owns 0.07% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 7,500 shares. Qs Llc holds 2,611 shares. Tortoise Invest Management Lc holds 0% or 164 shares in its portfolio. The Illinois-based Guggenheim Lc has invested 0.02% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0% or 2,078 shares. Next owns 100 shares or 0% of their US portfolio. Fred Alger stated it has 723,731 shares or 0.18% of all its holdings. Citigroup Inc has 60,014 shares for 0% of their portfolio. 478,690 were reported by Pictet Asset Ltd. First Quadrant LP Ca accumulated 947 shares. Huntington Bank & Trust invested 0% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). California State Teachers Retirement Sys has invested 0.01% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: